NCT03401320View on ClinicalTrials.gov

Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 6, 2017

Primary Completion Date

May 17, 2024

Study Completion Date

May 17, 2024

Conditions
Healthy
Interventions
DRUG

Letrozole ISM

2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM

Trial Locations (1)

10

Investigational Site Number 42001, Prague

All Listed Sponsors
lead

Rovi Pharmaceuticals Laboratories

INDUSTRY

NCT03401320 - Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1) | Biotech Hunter | Biotech Hunter